← AgentSite Network

ipsen.com

AI-friendly mirror of ipsen.com for archive, retrieval, and machine reading.

Total Pages
50
Total Words
44,575
Cache Generated
September 7, 2026
Resources
llms.txt— AI crawler index
sitemap.xml— XML sitemap
robots.txt— crawler directives
About this Cache— methodology and usage notes
Content Index
▸website50 pages
Homepage
Ipsen Media Library | Ipsen Global
▸press-release25 pages
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business
Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
… 20 more pages
Investors - Suscribe to Ipsen News - Global
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio - Global
▸careers3 pages
Work at Ipsen and discover the benefits | Ipsen Global
Explore Careers at Ipsen | Ipsen Global
Discover Ipsen Values : Way of Being | Ipsen Global
view all 3 pages
▸investors6 pages
Ipsen Investors | Investment Information & Updates
Shareholders Information at Ipsen | Valuable Insights for Shareholders
Investor Events at Ipsen | Engaging with Our Investor Community
Financial Results at Ipsen | Detailed Financial Performance
Reports and Accounts at Ipsen | Comprehensive Financial Information
… 1 more pages
Ipsen responsibility: Governance
Ipsen Media Updates | Official Announcements & Updates
▸sustainability2 pages
Governance at Ipsen | Upholding Ethical Business Practices
Corporate social responsibility | Ipsen Global
view all 2 pages
Newsroom - Subscribe to Ipsen News - Global
▸us2 pages
Compliance - United States
5 Ways Ipsen Keeps Compliance at Our Core - United States
view all 2 pages
Cabozantinib Ipsen® (cabozantinib) accepted by Scottish Medicines Consortium for adults with advanced neuroendocrine tumours - UK Ireland
Morgan Stanley Healthcare Conference - Global
Dysport® (AbobotulinumtoxinA) - Germany
2025 Integrated Annual Report - Global
Our 2025 Sustainability Statement is Live: Here's What It Means for Ipsen - Global